(Z)-10,11-dihydro-10-hydroxyimino-5H-dibenzo[b,f]azepine-5-carboxamide | 446063-97-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: (Z)-10,11-dihydro-10-hydroxyimino-5H-dibenzo[b,f]azepine-5-carboxamide
• 英文别名: Unii-8xmn58GM92；(5Z)-5-hydroxyimino-6H-benzo[b][1]benzazepine-11-carboxamide
• CAS: 446063-97-4
• 化学式: C₁₅H₁₃N₃O₂
• 分子量: 267.287
• InChiKey: VKSIBVBEGLEBSB-ATVHPVEESA-N

物化性质

• 沸点：
  498.1±55.0 °C(Predicted)
• 密度：
  1.36±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  20
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  78.9
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  10,11-dihydro-10-hydroxyimino-5H-dibenz[b,f]azepine-5-carboxamide 以 水 、 乙腈 为溶剂， 以16.8%的产率得到(Z)-10,11-dihydro-10-hydroxyimino-5H-dibenzo[b,f]azepine-5-carboxamide
  参考文献：
  名称：

  Synthesis, anticonvulsant properties and pharmacokinetic profile of novel 10,11-dihydro-10-oxo-5H-dibenz/b,f/azepine-5-carboxamide derivatives

  摘要：

  A series of novel derivatives of oxcarbazepine (5), 10,11-dihydro-10-oxo-5H-dibenz/b,f/azepine-5-carboxamide was synthesised and evaluated for their anticonvulsant activity and sodium channel blocking properties. The oxime 8 was found to be the most active compound from this series, displaying greater potency than its geometric isomer 9 and exhibiting also the highest protective index value. Importantly, the metabolic profile of 8 differs from the already established dibenz/b,f/azepine-5-carboxamide drugs such as 1 and 5 which undergo rapid and complete conversion in vivo to several biologically active metabolites. In contrast 8 is metabolised to only a very minor extent leading to the conclusion that the observed anti-convulsant effect is solely attributable to 8. It is concluded that 8 may be as effective as 1 and 5 at controlling seizures and that the low toxicity and consequently high protective index should provide the compound with an improved side-effect profile. (C) 2001 Editions scientifiques et medicales Elsevier SAS.

  DOI：

  10.1016/s0223-5234(01)01220-x

文献信息

• Derivatives of 10,11-dihydro-10-oxo-5h-dibenz/b,f/azepine-5-carboxamide
  申请人：Portela & Ca., S.A.

  公开号：EP0810216B1

  公开（公告）日：2001-03-21
• METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN POLYMERIZATION
  申请人：Perlmutter David Hirsch

  公开号：US20120129839A1

  公开（公告）日：2012-05-24

  The present invention relates to methods of treatment of clinical disorders associated with protein polymerization comprising administering, to a subject, an effective amount of carbamazepine, oxcarbazepine or another carbamazepine-like compound. It is based, at least in part, on the discovery that, in cells having a genetic defect in α1-antitrypsin, carbamazepine was able to decrease levels of the mutant protein. Furthermore, carbamazepine reduced the hepatic load of mutant α1-antitrypsin and the toxic effect of that mutant protein accumulation, hepatic fibrosis, in vivo using a mouse model of the disease. As patients having this defect in α1-antitrypsin exhibit toxic accumulations of the protein, treatment according to the invention may be used to ameliorate symptoms and signs of disease.
• TREATMENT OF TISSUE DISORDERS
  申请人：University of Newcastle Upon Tyne

  公开号：US20190076440A1

  公开（公告）日：2019-03-14

  Aspects of the present invention relate inter alia to the treatment of disorders which are characterised by inappropriate intracellular protein accumulation using carbamazepine and/or a carbamazepine-like compound. Also described herein are methods of treating such disorders comprising administering a composition comprising carbamazepine or a carbamazepine-like compound to a subject in need thereof. Exemplary disorders include for example connective tissue disorders.
• US8906905B2
  申请人：——

  公开号：US8906905B2

  公开（公告）日：2014-12-09
• US9511074B2
  申请人：——

  公开号：US9511074B2

  公开（公告）日：2016-12-06